Systemic Sclerosis (Scleroderma) - Pipeline Review, Q2 2011

FOR IMMEDIATE RELEASE
Navi Mumbai, Maharashtra, India, Republic of (Free-Press-Release.com) August 30, 2011 -- Systemic Sclerosis (Scleroderma)

This report provides information on the therapeutic development for Systemic Sclerosis (Scleroderma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Sclerosis (Scleroderma). 'Systemic Sclerosis (Scleroderma) - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
http://www.bharatbook.com/detail.asp?id=195090&rt=Systemic-Sclerosis-Scleroderma-Pipeline-Review-Q2-2011.html

- A snapshot of the global therapeutic scenario for Systemic Sclerosis (Scleroderma).
- A review of the Systemic Sclerosis (Scleroderma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Systemic Sclerosis (Scleroderma) pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Systemic Sclerosis (Scleroderma).

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) pipeline depth and focus of Systemic Sclerosis (Scleroderma) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=195090&rt=Systemic-Sclerosis-Scleroderma-Pipeline-Review-Q2-2011.html

Related Reports

Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, Q2 2011 
Or

Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/#!/BharatBook

chest back     face trunk     helthcare     market demand     market growth     market share     market size     skin